Cancer Biology

1312 O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation.

1311 Immature natural killer cells promote progression of triple-negative breast cancer.

1310 Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050.

1309 Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors.

1308 Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer.

1307 Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2.

1306 An HLA-G/SPAG9/STAT3 axis promotes brain metastases.

1305 Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.

1304 Slow TCA flux and ATP production in primary solid tumours but not metastases.

1303 Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.

1302 Dendritic cells direct circadian anti-tumour immune responses.

1301 PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia.

1300 An Integrated Polymeric mRNA Vaccine without Inflammation Side Effects for Cellular Immunity Mediated Cancer Therapy.

1299 Autonomous rhythmic activity in glioma networks drives brain tumour growth.

1298 Ferritin-Hijacking Nanoparticles Spatiotemporally Directing Endogenous Ferroptosis for Synergistic Anticancer Therapy.

1297 Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2.

1296 Ferroptosis of tumour neutrophils causes immune suppression in cancer.

1295 Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer.

1294 Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer.

1293 A poor prognosis gene programme in patients with colorectal cancer is expressed by a unique tumour cell population that we name high-relapse cells (HRCs), and ablation of cells expressing the HRC marker EMP1 or neoadjuvant immunotherapy prevented metastatic recurrence in animal models.

Free Images for Presentation: sunipix SUNIPIX